{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:11:27Z","timestamp":1782486687017,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Federal Ministry of Education and Research Germany"},{"name":"IFB AdiposityDiseases"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"German Hypertension League DHL e.V."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.cyto.2016.04.015","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T10:02:02Z","timestamp":1462960922000},"page":"239-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Serum concentrations of fibroblast growth factor 21 are elevated in patients with congenital or acquired lipodystrophy"],"prefix":"10.1016","volume":"83","author":[{"given":"Konstanze","family":"Miehle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kralisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annett","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Kratzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiko","family":"Schl\u00f6gl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stumvoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Fasshauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2016.04.015_b0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0092-8674(01)00240-9","article-title":"Obesity and the regulation of energy balance","volume":"104","author":"Spiegelman","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2016.04.015_b0010","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.3390\/nu6115153","article-title":"Obesity: pathophysiology and intervention","volume":"6","author":"Zhang","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.cyto.2016.04.015_b0015","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2016.04.015_b0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tips.2015.04.014","article-title":"Adipokines in health and disease","volume":"36","author":"Fasshauer","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cyto.2016.04.015_b0025","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2016.04.015_b0030","first-page":"107","article-title":"The clinical approach to the detection of lipodystrophy - an AACE consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol."},{"key":"10.1016\/j.cyto.2016.04.015_b0035","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2016.04.015_b0040","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2016.04.015_b0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cen.12095","article-title":"Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives","volume":"78","author":"Woo","year":"2013","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.cyto.2016.04.015_b0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.drudis.2013.10.021","article-title":"Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome","volume":"19","author":"Zhang","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cyto.2016.04.015_b0055","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2016.04.015_b0060","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.cyto.2016.04.015_b0065","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.115.015308","article-title":"Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice","volume":"131","author":"Lin","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2016.04.015_b0070","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2337\/dc09-0684","article-title":"Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance","volume":"32","author":"Chavez","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2016.04.015_b0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-12-0367","article-title":"Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans","volume":"216","author":"Kralisch","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.cyto.2016.04.015_b0080","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cyto.2013.02.019","article-title":"Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia","volume":"62","author":"Stepan","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2016.04.015_b0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jhep.2012.10.029","article-title":"High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China","volume":"58","author":"Li","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cyto.2016.04.015_b0090","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/09513590.2010.487587","article-title":"Serum fibroblast growth factor 21 levels in polycystic ovary syndrome","volume":"26","author":"Gorar","year":"2010","journal-title":"Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol."},{"key":"10.1016\/j.cyto.2016.04.015_b0095","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/cen.12380","article-title":"Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction","volume":"80","author":"Hindricks","year":"2014","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.cyto.2016.04.015_b0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/dc08-1054","article-title":"Serum levels of the adipokine FGF21 depend on renal function","volume":"32","author":"Stein","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2016.04.015_b0105","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1097\/QAD.0b013e3283400088","article-title":"Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients","volume":"24","author":"Domingo","year":"2010","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.cyto.2016.04.015_b0110","doi-asserted-by":"crossref","first-page":"e55632","DOI":"10.1371\/journal.pone.0055632","article-title":"Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV","volume":"8","author":"Lindegaard","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2016.04.015_b0115","article-title":"Circulating serum chemerin levels are elevated in lipodystrophy","author":"Miehle","year":"2015","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.cyto.2016.04.015_b0120","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.cyto.2016.04.015_b0125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cyto.2016.04.015_b0130","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00125-009-1466-9","article-title":"Metabolic effects of diets differing in glycaemic index depend on age and endogenous glucose-dependent insulinotrophic polypeptide in mice","volume":"52","author":"Isken","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.cyto.2016.04.015_b0135","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/oby.21057","article-title":"Circulating adipocyte fatty acid-binding protein induces insulin resistance in mice in vivo","volume":"23","author":"Kralisch","year":"2015","journal-title":"Obes. Silver Spring Md."},{"key":"10.1016\/j.cyto.2016.04.015_b0140","first-page":"3089","article-title":"LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration","volume":"85","author":"Hegele","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2016.04.015_b0145","doi-asserted-by":"crossref","first-page":"e40164","DOI":"10.1371\/journal.pone.0040164","article-title":"FGF21 promotes metabolic homeostasis via white adipose and leptin in mice","volume":"7","author":"V\u00e9niant","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2016.04.015_b0150","first-page":"483","article-title":"Changes in FGF21 serum concentrations and liver mRNA expression in an experimental model of complete lipodystrophy and insulin-resistant diabetes","volume":"63","author":"Spolcov\u00e1","year":"2014","journal-title":"Physiol. Res. Acad. Sci. Bohemoslov."},{"key":"10.1016\/j.cyto.2016.04.015_b0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mce.2011.07.026","article-title":"The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro","volume":"348","author":"Li","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.cyto.2016.04.015_b0160","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/db09-1878","article-title":"Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats","volume":"59","author":"Sarruf","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.cyto.2016.04.015_b0165","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.cyto.2016.04.015_b0170","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1210\/jc.2008-2331","article-title":"Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects","volume":"94","author":"Li","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2016.04.015_b0175","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2337\/dc11-0294","article-title":"High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects","volume":"34","author":"Chen","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2016.04.015_b0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.metabol.2009.07.003","article-title":"Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia","volume":"59","author":"Stein","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.cyto.2016.04.015_b0185","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.2337\/db08-1775","article-title":"Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21","volume":"58","author":"Mai","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.cyto.2016.04.015_b0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab."},{"key":"10.1016\/j.cyto.2016.04.015_b0195","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1210\/jc.2009-0111","article-title":"Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man","volume":"94","author":"Christodoulides","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2016.04.015_b0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.cyto.2016.04.015_b0205","first-page":"922","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol."},{"key":"10.1016\/j.cyto.2016.04.015_b0210","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616300734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616300734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:01:23Z","timestamp":1657238483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466616300734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":42,"alternative-id":["S1043466616300734"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2016.04.015","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum concentrations of fibroblast growth factor 21 are elevated in patients with congenital or acquired lipodystrophy","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2016.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}